Protein Acetylation Increased Risk of Fibrosis-Related Liver Cancer

Yuan Li,Yanyan Wang,Zhaopu Song,Kai Lu,Wenwen Chen,Yuanyuan Ma,Hui Ding,Xiaofang Li,Xiuling Li,Suofeng Sun

DOI: https://doi.org/10.1155/2023/3624635

IF: 4.501

2023-01-24

Journal of Oncology

Abstract:Objective. The occurrence of liver fibrosis and fibrosis-related liver cancer is the reason for the increase in morbidity and mortality worldwide. Transforming growth factor-β2 (TGF-β2) is an important mediator of chronic liver fibrosis. This study aims to find the molecular mechanism that mediates HBV infection and induces TGF-β2 and verifies that CREB binding protein acetylation mediates HBV infection and induces TGF-β2 expression. Methods. The acetylated proteins were extracted from HepG2-NTCP cells and HBV-infectedHepG2-NTCP cells. The acetylated proteins were screened by modification enrichment technology and database search. Protein annotation, motif analysis of modification sites, and protein function enrichment analysis of these proteins were performed to roughly clarify the location and function of these acetylated modification proteins in cells. Acylated proteins enriched in the TGF-β pathway were obtained by KEGG pathway enrichment analysis. The effect of the selected acetylated modification protein on the TGF-β pathway was verified by experiments, that is, the target protein gene was knocked out by siRNA, and the expression level of the TGF-β2 was detected by qRT-PCR. Results. Proteins were extracted from HepG2-NTCP cells and HepG2-NTCP cells infected with HBV, and differential acetylation modification proteins were screened. The target protein CREB binding protein was screened by modification enrichment technology and database search. The aggregation analysis of TGF-β pathway showed that CREB binding protein was acetylated at amino acid positions 434 and 439, and enriched in the TGF-β signaling pathway. siRNA targeting CREB binding protein was transfected, and the expression of TGF-β2 in cells was detected by qRT-PCR and western blot, respectively. It was verified that HBV infection-inducedCREB-binding protein acetylation regulated the high expression of TGF-β2. Conclusion. After HBV infection, CREBBP acetylation was up-regulated, which promoted the high expression of TGF-β2.

oncology

What problem does this paper attempt to address?

The paper primarily explores how Hepatitis B Virus (HBV) infection increases the risk of Transforming Growth Factor-β2 (TGF-β2) by promoting the acetylation of CREB-binding protein (CREBBP), which in turn leads to fibrosis-related liver cancer.

Specifically, the study addresses the following key issues:
1. **Relationship between HBV infection and TGF-β2 expression**: The paper reveals that HBV infection can upregulate the acetylation level of CREBBP and induce high expression of TGF-β2, which is an important step in the development of liver fibrosis.
2. **Molecular mechanism**: Researchers found that CREBBP is acetylated at amino acid positions 434 and 439, and this acetylation modification is enriched in the TGF-β signaling pathway, indicating that the acetylation of CREBBP directly participates in regulating the expression of TGF-β2.
3. **Experimental validation**: Through cell experiments and immunohistochemical analysis of liver cancer tissue samples, it was confirmed that HBV infection indeed leads to elevated levels of TGF-β2 expression, and high expression of TGF-β2 was observed in HBV-related liver cancer tissues.
4. **Therapeutic significance**: These findings provide a theoretical basis for developing new therapies targeting liver fibrosis, particularly by regulating the acetylation state of CREBBP to control the expression of TGF-β2, thereby reducing the risk of liver fibrosis and liver cancer.

In summary, this study provides a new perspective for understanding the molecular mechanisms by which HBV infection leads to liver fibrosis and its progression to liver cancer, and points the way for future development of anti-fibrosis drugs.